Clinical Trial Update: Managed Access Programs for PKC412, Midostaurin

View source ↗

Summary

This update indicates that Novartis' managed access programs for midostaurin (PKC412) are no longer available, impacting access for patients with FLT3-mutated a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis with An Associated Hematologic Neoplasm

Drugs mentioned

• Midostaurin (midostaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia, Acute Myeloid Leukemia | Status: NO_LONGER_AVAILABLE